Concepedia

Shenghui Tang

ST

86

Publications

7.2K

Citations

49

H-Index

1995

Active since

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Center for Devices and Radiological Health

University of Alabama at Birmingham

Shenghui Tang is an author at United States Food and Drug Administration specializing in medicine, oncology, and cancer therapeutics.

Top concepts

MedicineOncologyCancer TherapyClinical TrialsPharmacotherapyPharmacologyCancer ResearchRadiation OncologyHealthMolecular Oncology

Publications per year

1995–2025

86

Publications

86

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Laleh Amiri‐Kordestani, Gideon M. Blumenthal, Qiang Xu et al. · Clinical Cancer Research · 2014 · 336 citations

Metastatic Breast Cancer, Independent Review Committee, Breast Oncology +13

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

V. Ellen Maher, Laura L. Fernandes, Chana Weinstock et al. · Journal of Clinical Oncology · 2019 · 336 citations

Chemotherapy for Human Immunodeficiency Virus–Associated Non-Hodgkin’s Lymphoma in Combination With Highly Active Antiretroviral Therapy

Lee Ratner, Jeannette Y. Lee, Shenghui Tang et al. · Journal of Clinical Oncology · 2001 · 278 citations

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

Jaleh Fallah, Sundeep Agrawal, Haley Gittleman et al. · Clinical Cancer Research · 2022 · 200 citations · Full text

Urology, Dry Mouth, Genitourinary Cancer +14

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy

Daniel L. Suzman, Sundeep Agrawal, Yang-Min Ning et al. · The Oncologist · 2018 · 199 citations · Full text

Rows per page

1–5 of 86